Xiang Dapeng, Tian Bin, Yang Tianyao, Li Zhiyu
Department of General Surgery, Second Affiliated Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Department of General Surgery, Zhuji Central Hospital, Shaoxing, China.
Medicine (Baltimore). 2019 Jun;98(25):e16050. doi: 10.1097/MD.0000000000016050.
miR-222 is one of the most consistently overexpressed miRNAs in papillary thyroid carcinoma (PTC). Previous studies demonstrated that miR-222 overexpression conferred high-risk features in PTC patients, suggesting its value in risk-stratification. However, studies in term of miR-222's utility on stratifying PTCs are lacking.
One hundred patients including 10 with multinodular goiter and 90 with PTC were enrolled. Formalin-fixed paraffin-embedded samples were exploited for miR-222 quantitative reverse transcriptase- polymerase chain reaction (RT-PCR) analysis. Correlations between miR-222 expression and different clinicopathological features, Tumor-node-metastasis (TNM) staging and ATA risk level were analyzed.
miR-222 expression of the PTC group was significantly higher than that of the goiter group (P < .001). Furthermore, miR-222 expression was significantly higher in PTCs with advanced features like larger tumor, capsular invasion, vascular invasion and lymph nodes metastasis. The majority of patients (61%) were in stage I group (similar to ATA low-risk) by TNM staging system. As to the ATA system, the majority (73%) were in intermediate-risk group (similar to TNM stage II and III roughly). Contrary to previous report, here we found that miR-222 expression was correlated with the ATA risk level (P < .001), but not with the TNM staging (P = .122).
In the present study, we demonstrated that miR-222 overexpression was correlated with advanced features like capsular invasion, vascular invasion, larger tumor size and lymph node metastasis in PTCs. Most importantly, miR-222 expression was correlated with ATA risk levels, suggesting its potential value in PTC risk-stratification.
miR - 222是甲状腺乳头状癌(PTC)中最常持续过度表达的微小RNA之一。先前的研究表明,miR - 222的过度表达赋予PTC患者高风险特征,提示其在风险分层中的价值。然而,关于miR - 222在PTC分层中的应用研究尚缺乏。
纳入100例患者,其中10例为结节性甲状腺肿,90例为PTC。采用福尔马林固定石蜡包埋样本进行miR - 222定量逆转录聚合酶链反应(RT - PCR)分析。分析miR - 222表达与不同临床病理特征、肿瘤-淋巴结-转移(TNM)分期及美国甲状腺协会(ATA)风险水平之间的相关性。
PTC组miR - 222表达显著高于甲状腺肿组(P < 0.001)。此外,在具有较大肿瘤、包膜侵犯、血管侵犯和淋巴结转移等晚期特征的PTC中,miR - 222表达显著更高。根据TNM分期系统,大多数患者(61%)处于I期组(大致类似于ATA低风险)。对于ATA系统,大多数(73%)处于中度风险组(大致类似于TNM II期和III期)。与先前报道相反,我们在此发现miR - 222表达与ATA风险水平相关(P < 0.001),但与TNM分期无关(P = 0.122)。
在本研究中,我们证明miR - 222的过度表达与PTC中的包膜侵犯、血管侵犯、更大肿瘤大小和淋巴结转移等晚期特征相关。最重要的是,miR - 222表达与ATA风险水平相关,提示其在PTC风险分层中的潜在价值。